## Today’s Agenda

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Remarks</td>
<td><strong>Larry Culp</strong>, Chairman of the Board</td>
</tr>
<tr>
<td>Vision &amp; Strategy for Long-Term Value Creation</td>
<td><strong>Peter Arduini</strong>, CEO</td>
</tr>
<tr>
<td>Imaging</td>
<td><strong>Jan Makela</strong>, Imaging CEO</td>
</tr>
<tr>
<td>Ultrasound</td>
<td><strong>Roland Rott</strong>, Ultrasound CEO</td>
</tr>
<tr>
<td>Patient Care Solutions</td>
<td><strong>Thomas Westrick</strong>, Patient Care Solutions CEO</td>
</tr>
<tr>
<td>Pharmaceutical Diagnostics</td>
<td><strong>Kevin O’Neill</strong>, Pharmaceutical Diagnostics CEO</td>
</tr>
<tr>
<td>Commercial Strategy and Execution</td>
<td><strong>Catherine Estrampes</strong>, U.S. &amp; Canada, CEO</td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>Segment Leaders and <strong>Peter Arduini</strong></td>
</tr>
<tr>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>Financial Strategy</td>
<td><strong>Helmut Zodl</strong>, CFO</td>
</tr>
<tr>
<td>Q&amp;A</td>
<td><strong>Peter Arduini</strong> and <strong>Helmut Zodl</strong></td>
</tr>
<tr>
<td>Closing Remarks</td>
<td><strong>Peter Arduini</strong></td>
</tr>
</tbody>
</table>

© 2022, General Electric Company. Proprietary information. All rights reserved.
Disclaimer

This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company’s expected financial performance and financial condition, including revenue growth, profit, cash flows, and earnings per share and the Company’s 2022 outlook; taxes; the impacts of macroeconomic and market conditions and volatility on the Company’s business operations, financial results and financial position and on the global supply chain and world economy; the Company’s strategy, innovation and investments; the Company’s cost structure; the Company’s funding and liquidity; and the impacts of the COVID-19 pandemic. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause our actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; demand for the Company’s products, services, or solutions and factors that affect that demand; management of the Company’s supply chain and the Company’s ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company’s operations; the global COVID-19 pandemic and its effects on the Company’s business; maintenance and protection of the Company’s intellectual property rights; the impact of potential information technology, cybersecurity or data security breaches; compliance with the various legal, regulatory, tax, and other laws to which the Company is subject and related changes, claims, or actions; environmental, social, and governance matters; the Company’s ability to successfully complete strategic transactions; the Company’s ability to operate effectively as an independent, publicly-traded company and achieve the benefits the Company expects from its spin-off from General Electric Company; and the incurring of substantial indebtedness in connection with the spin-off and any related effect on the Company’s business. Please also see the “Risk Factors” section of the Company’s Form 10 filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Use of Non-GAAP Financial Measures
In this presentation, we use some information derived from consolidated financial data but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). These are considered “non-GAAP financial measures” under SEC rules. These non-GAAP financial measures supplement our disclosures and should not be considered an alternative to the comparable GAAP measure. Please see the end of this presentation for GAAP to non-GAAP reconciliations including comparable GAAP measures, and please see our Form 10 for more information on the reasons we use these non-GAAP financial measures.

Financial Comparisons
References to results increasing, decreasing, or remaining flat are in comparison to the same period in the prior fiscal year. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis.

Product Status
Not all products or features are available in all markets. The information presented here may involve technologies and concepts in development that are not products and may never become products. For Technology in Development, the technologies or concepts are not being offered for sale, and are not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

© 2022, General Electric Company. Proprietary information. All rights reserved.
Opening Remarks

Larry Culp
Chairman of the Board
Catalyst Moment

Greater focus and accountability to serve patients and customers

Team alignment ... dedicated talent, Board of Directors, and investors

Enhanced capital allocation and strategic flexibility
Experienced and Diverse Board of Directors

LARRY CULP
Chairman & CEO, GE; CEO, GE Aerospace

PETER ARDUINI
CEO, GE HealthCare

DR. RODNEY F. HOCHMAN
President and CEO of Providence St. Joseph Health

LLOYD W. HOWELL, JR.
CFO and Treasurer of Booz Allen Hamilton Holding Company

DR. RISA LAVIZZO-MOUREY
Former CEO of the Robert Wood Johnson Foundation

CATHERINE LESJAK
Former CFO of HP

ANNE T. MADDEN
SVP and General Counsel of Honeywell International

DR. TOMISLAV MIHALJEVIC
CEO and President of Cleveland Clinic

WILLIAM J. STROMBERG
Non-executive Chair of the Board of T. Rowe Price Group

PHOEBE L. YANG
Former GM at Amazon Web Services, Healthcare
Highly Qualified Leadership Team Driving Growth

- Strong track record of growth, innovation and operational execution
- Extensive industry and customer knowledge
- Deep experience in healthcare and M&A

Focused Company Driving Precision Care, Well-positioned To Create Significant Value
Vision and Strategy for Long-Term Value Creation

Peter Arduini
CEO
GE HealthCare

Create a world where healthcare has no limits
Accomplished Leadership Team with Strong Track Record
Clear Path to Accelerate Long-Term Shareholder Value

Global Leader in Attractive, Growing Market

Executing on Precision Care Strategy

Increased Focus and Agility

Driving Growth

- Mid-single digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT Margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

*Non-GAAP Financial Measure. Medium-term targets.
Clear Path to Accelerate Long-Term Shareholder Value

- Global Leader in Attractive, Growing Market
- Executing on Precision Care Strategy
- Increased Focus and Agility

Driving Growth:

- Mid-single digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT Margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

*Non-GAAP Financial Measure. Medium-term targets.
Leader in Attractive, Growing Global Market

$84 billion ➔ ~$100 billion
Total Addressable Market in 2021
Estimated by 2025

Global trends:

- Aging population
- Demand for insights & productivity
- Alternative sites of care

Attractive Growth Markets with Potential to Increase TAM With Adjacencies And White Spaces

(a - Source: GE HealthCare estimates, drawn from COCIR, NEMA, IPSOS, Signify, BCG, Bain. Includes radiotherapeutics, endoscopes, interventional devices and virtual hospital.)
## Leadership Positions in All Four Business Segments

<table>
<thead>
<tr>
<th>Segment</th>
<th>Industry Size '21 $</th>
<th>Industry CAGR '22-'25</th>
<th>End Market Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging</td>
<td>$44B</td>
<td>4-6%</td>
<td>Attractive Market</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>$12B</td>
<td>4-7%</td>
<td>Growing Market</td>
</tr>
<tr>
<td>Patient Care Solutions (PCS)</td>
<td>$18B</td>
<td>3-6%</td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Diagnostics (PDx)</td>
<td>$10B</td>
<td>4-5%</td>
<td></td>
</tr>
</tbody>
</table>

(a - Based on GE HealthCare estimates and Signify Research for digital solutions)

Global Leader in Attractive, Growing Market

Attractive End Markets Support Strong Growth Opportunities Across Segments
# GE HealthCare’s Extensive Reach at a Glance

<table>
<thead>
<tr>
<th>Patients served annually</th>
<th>~$1B Annual R&amp;D &amp; product investment spend</th>
<th>$18B Revenue (~50% recurring(^a))</th>
</tr>
</thead>
<tbody>
<tr>
<td>1B+</td>
<td>~18.5K Customer-facing employees</td>
<td>42 AI-enabled device authorizations in U.S., top of recent FDA list(^b)</td>
</tr>
<tr>
<td>Installed base</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4M+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: Figures as of 2021 unless otherwise noted
\(^a\) - Comprised of services, single-use and consumable products, digital solutions, and value-added offerings, such as education, training, and consulting
At the Forefront of Care Delivery Across the Patient Journey

Hospitals | Ambulatory Surgery Centers | Outpatient Clinics | Physicians’ Offices | Home

Prevention/Screening

Diagnosis

Treatment

Monitoring

Improving Patient Outcomes & Customer Productivity With Integrated Products & Installed Base Upgradeability
Clear Path to Accelerate Long-Term Shareholder Value

Global Leader in Attractive, Growing Market

Executing on Precision Care Strategy

Increased Focus and Agility

Driving Growth

- Mid-single digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT Margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

*Non-GAAP Financial Measure. Medium-term targets.
Precision Care leverages a patient’s unique data via multi-modal sources to determine the most appropriate treatment and deliver the best possible outcome.
Uniquely Positioned to Enable Precision Care

Sole Global MedTech Player With Equipment + Digital + Imaging Agents
Our Approach to Delivering Precision Care
New Product Introductions Driving Growth
Introduced ~40 New Products at RSNA 2022

Indicates AI integration

Revolution Apex

SIGNA™ (1.5 and 3T)

Omni Legend (PET / CT)

Portrait Mobile

Voluson Expert 22

CT Motion Injector

AIR™ Recon DL

OEC 3D

End-tidal Control Software

Vscan Air

Vivid Cardiology

Imaging

Ultrasound

Business Segments

Patient Care Solutions (PCS)

Pharmaceutical Diagnostics (PDX)

>35% Of Equipment Orders From NPIs In 2021-b) with continued strong growth in 2022

(a) Portrait Mobile CE marked and 510K pending in US. End-tidal-Control CE marked and FDA approved.
(b) Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months.

© 2022, General Electric Company. Proprietary information. All rights reserved.
Care Pathway Strategy Enables Precision Care

Cardiology Example

- CARESCAPE™
- RPM Edison™
- Allia™ IGS
- AI-powered CDS Suite
- MAC 2000
- MyoSPECT
- Myoview
- Vivid™
- Revolution™ Apex
- EDISON™ DIGITAL HEALTH PLATFORM

We Play Across the Care Continuum

(a) Technology in Development - not a commercial product
Creating an Open Health Care Ecosystem with Integrated Network Effect

Open Digital Platform to Drive Better Insights and Predictive Capabilities

Edison™ Digital Health Platform

GEHC Imaging Fabric
AI/ML Engine
Third-Party Vendor & Data Integration
Development Platform
Connected Care Pathways
Leading Devices

Executing on Precision Care Strategy

© 2022, General Electric Company. Proprietary information. All rights reserved.
Higher Commercial and R&D Spend to Drive Growth

Prioritizing Fastest-Growing Areas

<table>
<thead>
<tr>
<th>Area</th>
<th>Est. CAGR '22–'25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premium CT / PCCT</td>
<td>~10% b)</td>
</tr>
<tr>
<td>Cardio / 3-D Image-guided Therapies</td>
<td>~15%</td>
</tr>
<tr>
<td>Handheld Ultrasound</td>
<td>~20%</td>
</tr>
<tr>
<td>Oncology MI / Theranostics</td>
<td>20%+</td>
</tr>
<tr>
<td>MR Platforming</td>
<td>~5-7%</td>
</tr>
<tr>
<td>AI Solutions and Edison™ Platform</td>
<td>25%+ c)</td>
</tr>
</tbody>
</table>

Driving Organic Revenue Growth* & Adjusted EBIT*

Growing, Focused R&D Driving Innovation Releases Every 12-18 Months d)

* Non-GAAP Financial Measure
  (a - Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months.
  (b - Premium CT / Photon-Counting CT CAGR pertains to ‘18–30.
  (c - Refers to GEHC Edison™ platform and apps revenue growth rate. All other metrics refer to end market growth rates.
  (d - For most product lines.
External Investments to Enhance Precision Care Strategy

**ACQUISITIONS**

- **Prismatic sensors**
  - Photon-Counting Tech
  - Goal to make treatment faster and more precise

- **bk medical**
  - Surgical Visualization
  - Expanding into adjacencies

- **Zionexa**
  - Oncology and Neurology
  - Capitalizing on emerging trends

**COLLABORATIONS**

- **RaySearch Laboratories**
  - Radiation Oncology

- **SOPHiA GENETICS™**
  - Precision Oncology

- **AliveCor Pulsenmore**
  - Alternative Care Settings

Adding new capabilities for customers and patients

Pursuing Inorganic Investments to Complement our Leading Portfolio
Clear Path to Accelerate Long-Term Shareholder Value

Global Leader in Attractive, Growing Market

Executing on Precision Care Strategy

Increased Focus and Agility

Driving Growth

- Mid-single digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

*Non-GAAP Financial Measure. Medium-term targets.
Unique Culture Supports our Priorities for Growth

Building Our Winning Culture

Serve Our People, Patients, & Customers

Lead with Lean

Empower Entrepreneurial Spirit

Deliver The Future of Healthcare

Win Together with Inclusive Teams

Positioning our culture to enable success for our customers, patients and stakeholders
Optimizing our Operating Model as a Standalone Company

Four Focused & Integrated Segments:

- Imaging
- Ultrasound
- Patient Care Solutions (PCS)
- Pharmaceutical Diagnostics (PDx)

Simplified, Customer-centric Structure Increases Our Speed & Agility
Committed to Enhancing Our ESG Strategy

Prioritizing ESG to Support Long-Term Value Creation

Five Focus Areas

1. Access to healthcare
2. Climate impact & resilience
3. Circular economy & environmental design
4. Inclusion & diversity
5. Cybersecurity & patient data

Environment and Climate
- Goal to reduce emissions by 50% by 2030\(^{(a)}\)
- Net zero by 2050

Social Capital
- 31% of leadership female\(^{(b)}\)
- 27% ethnically diverse\(^{(c)}\)
- New Chief DE&I Officer

Governance and Leadership
- Enterprise Stewardship Program
- Completed materiality assessment

(a - Refers to Scope 1 and 2 absolute emissions versus a 2019 baseline.
(b - Leadership encompasses the top 1.5% of all active employees.
(c - Data representative of GE’s U.S. workforce as of December 31, 2021, extracted in January 2022.)
Clear Path to Accelerate Long-Term Shareholder Value

- Global Leader in Attractive, Growing Market
- Executing on Precision Care Strategy
- Increased Focus and Agility

Driving Growth

- Mid-single digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT Margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

*Non-GAAP Financial Measure. Medium-term targets.
## Executing on Clear Growth and Margin Drivers

### Growth Drivers
- Enhanced commercial execution and capabilities
- NPIs and commercial investments
- Digital platform / AI and SaaS solutions

### Margin Drivers
- Higher-margin products from innovation
- Strategic pricing and mix, including software
- Lean-driven operating model and optimization

---

### Imaging
- Higher-margin NPIs
- Platforming initiatives
- Digital / AI driving growth

### Ultrasound
- NPIs driving innovation
- Expand into adjacencies
- Broaden digital ecosystem

### PCS
- Commercial execution
- Lifecycle management
- New monitoring platforms

### PDx
- Capacity expansion
- Pricing optimization
- New products

---

**Clear Strategy To Drive Top- And Bottom-line Growth With Focused Strategy**
Long-Term Value Creation Framework

Driving Growth
MSD Organic Revenue Growth*

Adj EBIT Margin Expansion
High-teens to 20%*

Strong FCF* Generation

Disciplined Capital Allocation
Strong financial position
Investment in Organic growth
Investment in M&A

Shareholder Value Creation

*Non-GAAP Financial Measure. Medium-term targets.
Imaging

Jan Makela
Imaging CEO
Key Takeaways

✓ Well-positioned to capitalize on future growth with robust NPI pipeline in growth industries

✓ Recurring revenue, underpinned by services: ~50% of total GE HealthCare revenue

✓ Large, global installed base with growing fleet enterprise solutions, data integration and digital sales

✓ Expanding margins through NPIs, digitization, commercial & supply chain operations¹)

¹) Expanding margins is on forward looking basis
Imaging at a Glance

$44B\textsuperscript{a)}
Global End Markets

Estimated CAGR of 4-6\%\textsuperscript{b)}

$9,433M\textsuperscript{c)}
Revenue

13.1\%\textsuperscript{c)}
Segment EBIT Margin

Leadership positions in nearly all addressable markets

8,500 field service engineers\textsuperscript{d)}

One of largest global installed bases of 400K medical imaging devices

200+
Software applications

\textsuperscript{a)} Estimated for the year 2021
\textsuperscript{b)} Estimated for the period 2022-2025
\textsuperscript{c)} For the year 2021
\textsuperscript{d)} Includes all of GE HealthCare

© 2022, General Electric Company. Proprietary information. All rights reserved.
Attractive End Market Trends Driving Growth

Estimated End Markets

$44B end markets: 4-6% CAGR\(^a\)

New Procedures and Growing Healthcare Demand Driving Imaging Markets

- Increasing penetration of imaging technologies in diagnosis
- Growth in broad-based population screening programs
- Tech / AI expanding indications for high-end diagnostic exams
- New therapeutic procedures require precision imaging guidance

(a - Estimated from 2022-2025
(b - Represents the midpoint of the range

© 2022, General Electric Company. Proprietary information. All rights reserved.
# Industry-Leading Imaging Solutions

<table>
<thead>
<tr>
<th></th>
<th>Industry(^a)</th>
<th>Growth(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI &amp; CT</td>
<td>~$8B</td>
<td>~3-5%</td>
</tr>
<tr>
<td>MR</td>
<td>~$6B</td>
<td>~5-7%</td>
</tr>
<tr>
<td>X-Ray &amp; Women’s Health</td>
<td>~$4B</td>
<td>~1-3%</td>
</tr>
<tr>
<td>Image-Guided Therapies</td>
<td>~$4B</td>
<td>~4-6%</td>
</tr>
</tbody>
</table>

\(^a\) For the year 2021. Total Industry size shown here excludes service capabilities and digital solutions.

\(^b\) Estimated for the period 2022-2025.

© 2022, General Electric Company. Proprietary information. All rights reserved.
Redefining What is Possible with CT

Trends Increasing CT Demand

Population-based screening programs
- Low-dose Lung & Colorectal cancer screening
- Long Covid screening

Favorable reimbursement
- Trends in private insurance such as Cardiac (CCTA) with procedure volumes growing 5%\(^a\)

Artificial Intelligence adoption
- Optimizing workflows: image reconstruction, patient positioning and setup

Helping Our Healthcare Providers

Broad CT portfolio
- From industry-leading cardiac CT to high-throughput value models
- Improving accessibility

Subscription payment models & modular design
- Delivers CT scanners which keep getting better

Next-generation CT
- Advancing progress in Deep Silicon PCCT to quantity tissue parameters & characterize disease\(^b\)

\(^a\) - Estimated CAGR for the period 2019-2025
\(^b\) - Technology in development not a commercial product
Trends Increasing MR Demand

Radiomics (quantitative MRI) & AI
- Fueling research in neuroscience & oncology

MR delivers superior tissue specificity
- Early diagnosis: stroke, heart disease & cancer

Ideal for treatment monitoring & screening
- Non-ionizing radiation
- Optimizing cost and scan times

Upgradeability, Accessibility, Quality, Speed

Fast images & better quality
- AIR™ Recon DL, using Deep-Learning to remove image noise in raw data
  - ~5M patients scanned

Capital efficiency
- Field upgradeable across platforms
- World’s first 60 cm-to-70 cm fleet upgrade

Faster & easier for scanning
- AIR™ Coil (recognized by AuntMinnie.com, Best New Radiology Device 2019)
- Improving patient experience with AI workflow
Surgical Imaging Leadership

Surgical Shift Translating to Growth

Active aging population
• Leading to growth in orthopedic procedures (hip, knee & shoulder)

Dramatic expansion of procedure types
• Growth beyond hospitals at lower-cost ambulatory surgical centers & office-based labs

Surgical eco-system of imaging, procedure-navigation and robotics
• Expected to grow by 80%+ by 2025

Precision And Efficiency Of OEC 3D

OEC 3D & 3D Volume Viewer

Saves OR time
• True 2D & 3D capable; one product for many procedures

Seamless integration with existing OR workflows
• Planning & confirmation directly in the OR

Critical part of the full solution in Spine
• Flexible to interface with 6 Nav/Robotic 3rd parties

© 2022, General Electric Company. Proprietary information. All rights reserved.
Unique Portfolio Across Molecular Medicine

Increased Activity in Nuclear Medicine (NM)

Cancer: #2 cause of death globally

62%\(^{a)}\) surge in cancer incidence in the next two decades

32%\(^{b)}\) annual growth in Radiotherapeutics from 2020 to 2031 in NM markets with approvals of new drugs

Precision care leading to an expansion of clinical guidelines
  - Across oncology, neurology and cardiology

The Future of Molecular Imaging (MI) is Personal

Total MI for Theranostics –
GE’s comprehensive & industry-leading solution

- **Discovery**: Cyclotron, radiochemistry to drive production of new tracers
- **Diagnosis**: High-resolution digital PET/CT for staging and re-staging tumors
- **Treatment**: Powerful digital SPECT/CT with advanced AI-powered clinical apps

---


\(\text{b)}\) – Projected

\(\text{c)}\) 510(k) pending
Precision Care in the Oncology Care Pathway with D³

Disease State: Prostate Cancer

Patient Journey

Symptoms/Screening

Diagnosis

Staging

Treatment Planning

Therapy/Monitoring

Follow Up

Devices

Signa™ Artist MR
LOGIQ™ Ultrasound

Signa™ Architect MR
Omni Legend PET/CT
Revolution™ CT
Signa™ PET/MR

LOGIQ™ E10
Discovery™ RT CT
MR Radiation Oncology Suite

StarGuide™ SPECT/CT
OEC® Elite CFD

LOGIQ™ E10
Omni Legend PET/CT
Signa™ PET/MR + Quantworks

Digital/Data

Theranostics Solutions & Services, Q.Thera® AI Dosimetry & Quantitation

AW PROVIEW
Edison™ Datalogue

Centricity Universal Viewer™

Roadmap

Radiomics / Predictive Analytics

Integrated Care with EMR, Genomics, Pathology

Precision Radiotherapy (MR, CT, PET)

Remote Patient Monitoring

Well-Positioned to Serve Prostate Cancer Care Pathways

(a - 510(k) pending)
Unmatched Customer Experience Through Services

Comprehensive World-class Service Offering\(^a\)

\(\sim 50\%\) Total 2021 Recurring Revenue

\(\sim 35\%\) Digital Service Fix

+4.5 Days Per Year of Increased Uptime\(^b\)

Award-Winning Service

\(\text{a) Statistics for all GE HealthCare} \quad \text{b) Statistics for Imaging}\)

The Predictive Customer Experience

- Ability for Customers to Reach GEHC 24x7
- Multivendor Repair Capabilities
- LEAN Parts Planning
- Intelligent Remote Connectivity
- Lifecycle Management & System Upgradeable Strategy
- Efficient Commercial Upgrades & Replacements

© 2022, General Electric Company. Proprietary information. All rights reserved.
Imaging Historical Financial Summary

Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>Service Revenue</th>
<th>Total Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019A</td>
<td>$9.1B</td>
<td>$9.0B</td>
</tr>
<tr>
<td>2020A</td>
<td>$9.0B</td>
<td>$9.4B</td>
</tr>
<tr>
<td>2021A</td>
<td>$7.0B</td>
<td>$7.3B</td>
</tr>
<tr>
<td>2021 Q3 YTD</td>
<td>$7.0B</td>
<td></td>
</tr>
<tr>
<td>2022 Q3 YTD</td>
<td>$7.3B</td>
<td></td>
</tr>
</tbody>
</table>

Segment EBIT Margin

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019A</td>
<td>10.3%</td>
</tr>
<tr>
<td>2020A</td>
<td>13.2%</td>
</tr>
<tr>
<td>2021A</td>
<td>13.1%</td>
</tr>
<tr>
<td>2021 Q3 YTD</td>
<td>13.2%</td>
</tr>
<tr>
<td>2022 Q3 YTD</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

Key Drivers

- Customer Insights Driving Innovation
- Edison-enabled AI & Connectivity
- Large Installed Base with Upgrades & Service
- YTD Margin Compression As Pricing Flows Through
Strong Visibility to EBIT Margin Expansion

Recent Historical Segment EBIT Margin Range: ~10-13%

NPIs

Commercial Execution

Supply Chain, VCP & Platforming

Enterprise Fleet Solutions & Digital

Medium-term Target: High-teens

Note: Illustrative graph, not to scale
Our Growth Strategies to Drive Long-Term Success

- Focus on Execution
- Broaden Portfolio Leadership Across Care Pathways
- Deliver Industry-Leading Service Capabilities
- Expand Digital / AI Capabilities with Edison™
Ultrasound

Roland Rott
Ultrasound CEO
Key Takeaways

✓ GEHC defining the category for over 25 years

✓ Mid-single digit growing end markets with recent expansion into high-single digit adjacencies

✓ Care pathways, AI & digital innovation spearhead future growth

✓ Strong margin profile through scale/value creation
Ultrasound at a Glance

- Leadership position in nearly all addressable markets
- $12B\textsuperscript{a)} Global End Markets
  - Industry CAGR of \(\sim 4\text{-}7\%\textsuperscript{b)}\)
- Large global installed base of \(~400K\) devices
- $3,172M\textsuperscript{a)} Revenue
- 27.9\%\textsuperscript{a)} Segment EBIT Margin
- 75K+ customers in on-line customer communities
- >600M Ultrasound exams performed annually

Source: GE HealthCare Estimates
(a - For the year 2021 – product and service
(b - Estimated for the period 2022-2025

© 2022, General Electric Company. Proprietary information. All rights reserved.
Mid-Single Digit Industry with High-Growth Adjacencies

Estimated End Markets\textsuperscript{a)}

$12B end markets: ~4-7% CAGR\textsuperscript{b)}

2021A  | $12B
2025E  | $15B\textsuperscript{c)}

Source: GE HealthCare Estimates
\textsuperscript{a) Including Digital Solutions of $1B and Service Capabilities of $4B
\textsuperscript{b) From 2022 – 2025
\textsuperscript{c) Represents the mid-point of the range

Strong Demand for Real-Time Radiation-Free Cost-Effective Imaging

- Compelling diagnostic capabilities and large installed base
- Accelerating industry expansion and adoption of therapy guidance, screening & Point-of-Care
- Strong growth in digital solutions and handheld industries
- Broad wireless, wearables & homecare acceptance
## Industry-Leading Ultrasound Portfolio
Spanning the Continuum of Care Including Screening\(^a\), Diagnosis, Treatment and Follow-up

| Product Portfolio Supported by Growing Demand for Digital Solutions and Service Capabilities |
| ~$3B | ~$1B | ~$1B | ~$1B | ~$1B |

### Radiology and Primary Care
- Industry\(^{b)}\): ~$3B
- Estimated Growth\(^{c)}\): ~4-6%

### Cardiovascular
- Industry\(^{b)}\): ~$1B
- Estimated Growth\(^{c)}\): ~3-5%

### Women’s Health
- Industry\(^{b)}\): ~$1B
- Estimated Growth\(^{c)}\): ~3-5%

### Point of Care & Handheld
- Industry\(^{b)}\): ~$1B
- Estimated Growth\(^{c)}\): ~8-10%

### Surgical Visualization & Guidance
- Industry\(^{b)}\): ~$1B
- Estimated Growth\(^{c)}\): ~10%+

---

**Source:** GE HealthCare Estimates
\(^a\) - Invenia ABUS or *Automated Breast Ultrasound*
\(^b\) - For the year 2021, Form 10 sub-segments and industry
\(^c\) - For the period 2022-2025, Form 10 CAGR
I can do my diagnosis much faster, more detailed, and I get better images, a lot better images. Therefore, I can see anomalies or have the impression that I don't miss anything I might have missed some years ago.

– Prof. Tilman Esser

25+ Years of Category Defining Innovation

Market-Defining Innovation

1990s 3D Fetal Ultrasound
2003 Real Time 4D
2010 Handheld Ultrasound
2018 AI Optimization
2021 Wireless Whole-Body Scanning
2022 Pediatric 4D TEE Probe

Improve Outcomes – Clinical Innovation
Enhancing Workflow Productivity – AI & Digital
Ubiquitous Ultrasound – Miniaturization

Innovation DNA & Customer Intimacy Will Continue to Drive Growth and Category Transformation

© 2022, General Electric Company. Proprietary information. All rights reserved.
Productivity Potential of AI in Ultrasound

From: 1-2 minutes
To: 10 seconds with the help of AI

Artificial Intelligence Implementation Enhancing Workflows and Expanding User Bases
Automation & AI – Opening Up New Markets

bkActiv
Empowering Smarter Surgery

Vscan Air
See More, Treat Faster

Voluson Expert 22
Healthier Future for Women

~50K Neurosurgeons
>235K General Surgeons

>1.1M Primary Care Physicians

>252M pregnancies per year

Driving Enterprise Productivity While Improving Patient Outcomes
Compounding Value Through AI & Digital Innovation

Care Team Collaboration
- Extends the care team with remote support
- Connects users in real-time

Reporting & Workflow
- Empowers clinicians by optimizing workflow
- Provides comprehensive patient information

Fleet Management
- Enables control of fleets of devices and probes

Powered by Edison™ Health Services

A Single Platform to Enhance Every Ultrasound Exam
# Ultrasound Historical Financial Summary

## Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019A</td>
<td>$2.8B</td>
</tr>
<tr>
<td>2020A</td>
<td>$2.7B</td>
</tr>
<tr>
<td>2021A</td>
<td>$3.2B</td>
</tr>
<tr>
<td>2021 3Q YTD</td>
<td>$2.3B</td>
</tr>
<tr>
<td>2022 3Q YTD</td>
<td>$2.5B</td>
</tr>
</tbody>
</table>

## Segment EBIT Margin

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019A</td>
<td>23.4%</td>
</tr>
<tr>
<td>2020A</td>
<td>23.7%</td>
</tr>
<tr>
<td>2021A</td>
<td>27.9%</td>
</tr>
<tr>
<td>2021 3Q YTD</td>
<td>26.7%</td>
</tr>
<tr>
<td>2022 3Q YTD</td>
<td>25.3%</td>
</tr>
</tbody>
</table>

## Key Drivers

- **Leading Position & Trusted Brand**
- **Global Distribution & Service Presence**
- **Innovating Smart Devices & Digital Solutions**
- **Continuous Improvement to Optimize Value Stream**
Growth Strategies Driving Long-Term Success

- Grow Leadership Position Through Innovation & Commercial Intensity
- Expand into Attractive Adjacencies
- Broaden Digital Capabilities and Ecosystem in Ultrasound
- Revenue Expansion through Value Creation & Scale
Patient Care Solutions

Thomas Westrick
Patient Care Solutions CEO
Key Takeaways

- Decades of clinical innovation & trusted solutions
- Ubiquitous, clinically excellent, monitoring solutions portfolio
- Growing digital solutions with clinical decision support
- Mature markets, mid-single-digit growth, with high-growth adjacencies
Patient Care Solutions at a Glance

- Clinical solutions providing real-time data, insights & support
- $18B\textsuperscript{a)} Global End Markets
- Estimated CAGR of 3-6\textsuperscript{b)}
- Every 0.2 seconds anesthesia delivered on a GEHC solution
- $2,915M\textsuperscript{c)} Revenue
- 12.2\%\textsuperscript{c)} Segment EBIT Margin
- Industry-leading positions in Monitoring Solutions, Anesthesia, Diagnostic EKG & Maternal Infant Care
- 100M patients monitored annually
- Large installed base 3 million devices

\textsuperscript{a) Estimated for the year 2021}
\textsuperscript{b) For the period 2022-2025}
\textsuperscript{c) For the year 2021}
# Strong Portfolio to Address Patient Care Needs

## Real-time critical care insights, visualization and decision support tools

<table>
<thead>
<tr>
<th>Category</th>
<th>Stabilize &amp; Triage</th>
<th>Surgical Care</th>
<th>Critical Care</th>
<th>Monitoring &amp; Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring Solutions</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Anesthesia &amp; Respiratory Care</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Diagnostic Cardiology</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Maternal Infant Care</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

© 2022, General Electric Company. Proprietary information. All rights reserved.
Solving for Today’s Healthcare Challenges

Estimated End Market Sizes\(^{a)}\)

\$18B end markets: 3-6% CAGR\(^{b)}\)
Digital solutions growing +10%

\$21B \(^{c)}\)

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021A</td>
<td>$18B</td>
</tr>
<tr>
<td>2025E</td>
<td>$21B</td>
</tr>
</tbody>
</table>

Numerous Macro Trends …

- Aging, clinically complex population
- Clinician shortages
- Inflationary pressure stressing healthcare viability

… Leading To Multiple Unmet Needs

- Connected and seamless data
- Real-time visualization …bedside or remote
- Workflow improvements with clinical decision support

\(^{a)}\) Including Digital Solutions of \$2B and Service Capabilities of \$4B
\(^{b)}\) For the Period 2022 – 2025
\(^{c)}\) Represents the midpoint of the range
Innovating to Meet Customer Need

## Industry Firsts
- Command Center
- MUSE EKG Management

## Innovation Pipeline

<table>
<thead>
<tr>
<th>Near-Term Major NPI Launches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major NPI (Innovation)</td>
</tr>
<tr>
<td>Other Programs (Iterations)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Monitoring &amp; Digital Solutions</th>
<th>Anesthesia &amp; Respiratory</th>
<th>Diagnostic Cardiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>2023</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>2024</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>2025</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
</tbody>
</table>

Accelerating Innovation Focused on Clinical Excellence and Workflow Solutions
Improving Outcomes with Monitoring & Digital Solutions

Monitoring Solutions

Recently Launched

FlexAcuity Offerings
Flexible monitoring to adapt with changing care needs

Post-Acute Monitoring
Wearable, wireless continuous post-acute monitoring

Digital Applications

Clinical Workflow Enhancements

Digital Centralized Monitoring
Real-time telemetry improving care collaboration and response time

MURAL
Real-time visualization and clinical decision support

Data Platform
Powered by Edison™ Health Services

Device-Led, Clinical Data Acquisition → Insights → Insights at Scale
Enhancing Health Systems Workflows

Command Center

Capture and Transform Data to Deliver Operational Workflow Improvements

Actionable Information Across Care Settings

- Capacity management
- Improved patient transitions
- Reduction of unnecessary transfers
- Reduction of length of stay

Customer Value

“What we were able to do in real-time, is understand where our beds will be later today and therefore, what patients we can accept now.”

– Dr. Sanjay Pattani
AdventHealth, Central Florida Division
PCS Historical Financial Summary

### Revenue

- **2019A:** $2.7B
- **2020A:** $3.7B
- **2021A:** $2.9B
- **2021 Q3 YTD:** $2.2B
- **2022 Q3 YTD:** $2.1B

### Segment EBIT Margin

- **2019A:** 9.7%
- **2020A:** 19.0%
- **2021A:** 12.2%
- **2021 Q3 YTD:** 12.2%
- **2022 Q3 YTD:** 9.9%

### Key Drivers

- **Increasing Innovation to Maintain and Advance Clinical Excellence**
- **Increasing the Use of Data at Scale to Advance Clinical & Operational Workflow Solutions**
- **Operational Improvements via Lean**
  - Supply chain
  - Lifecycle management

Poised to Drive Growth in Near-Term
Visible Path to EBIT Margin Expansion

~10-12%<sup>a</sup>

(a - Excludes 2020 due to COVID impact)

Note: Illustrative graph, not to scale
Our Growth Strategies to Drive Long-Term Success

Increase Innovation Across Portfolio

Drive Digital Solutions that Improve Patient Outcomes and Productivity

Improve Margin Through Services & Consumables Growth

Focus On Execution
Pharmaceutical Diagnostics

Kevin O'Neil
Pharmaceutical Diagnostics CEO
Key Takeaways

☑ Global leader in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging

☑ Driving innovation through funnel of new products and improving customer productivity

☑ Strong financial profile buoyed by recurring revenues and strong margins, built on a foundation of global commercial reach and a vertically integrated supply chain
Pharmaceutical Diagnostics at a Glance

Products used in over 100M patient procedures

$10B Global End Markets

$2,018M Revenue

34.3% Segment EBIT Margin

Only imaging provider that also manufactures diagnostic pharmaceuticals

7 cGMP Manufacturing Sites

Industry CAGR of ~4-5%

20+ Brands

71 Pre-clinical or clinical pipeline assets

Source: GE HealthCare Estimates
(a - For the year 2021
(b - Estimated for the period 2022-2025
(c - Current Good Manufacturing Practices
Recurring Consumables Revenue, Mid-Single Digit Growth

Estimated End Markets

$10B end markets: 4-5% CAGR\(^{(a)}\)

Tailwinds Driving Demand In Attractive End Markets

- Demand for innovative therapies & precision diagnostics
- Growth in contrast media utilization
- Aging populations and chronic disease prevalence
- Expanding patient access elevating number of procedures

(a - Estimated from 2022-2025
(b - Represents the midpoint of the range

© 2022, General Electric Company. Proprietary information. All rights reserved.
# Pharmaceutical Diagnostics and What We Do

<table>
<thead>
<tr>
<th>Administered to Patient, Image Captured</th>
<th>Amplified Diagnostic Images</th>
<th>Enhanced Clinical Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contrast Media</strong>&lt;sup&gt;a)&lt;/sup&gt;</td>
<td>Structural Imaging Focus</td>
<td></td>
</tr>
<tr>
<td><img src="image1" alt="Contrast Media Image" /></td>
<td><img src="image2" alt="Structural Imaging Image" /></td>
<td><img src="image3" alt="Enhanced Clinical Decisions Image" /></td>
</tr>
<tr>
<td><strong>Molecular Imaging</strong>&lt;sup&gt;b)&lt;/sup&gt;</td>
<td>Functional Imaging Focus</td>
<td></td>
</tr>
<tr>
<td><img src="image4" alt="Molecular Imaging Image" /></td>
<td><img src="image5" alt="Functional Imaging Image" /></td>
<td><img src="image6" alt="Clinical Decisions Image" /></td>
</tr>
</tbody>
</table>

**Enabling Better Patient Outcomes**

(a) X-ray, CT, MR, Interventional, and Ultrasound  
(b) Radioactive tracers used in SPECT and PET procedures

© 2022, General Electric Company. Proprietary information. All rights reserved.
### Diagnostic Agent Portfolio with Industry-wide Compatibility

#### Contrast Media
- Injectable agents used to improve visualization and diagnostic value of scans
- Industry: ~$5B
- Estimated Growth: Mid-Single Digit %

#### Molecular Imaging
- Radioactive tracers used in SPECT & PET procedures
- Industry: ~$5B
- Estimated Growth: Mid-Single Digit %

<table>
<thead>
<tr>
<th>X-Ray/CT</th>
<th>MR</th>
<th>Ultrasound</th>
<th>SPECT</th>
<th>PET</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMNIPAQUE (IOHEXOL) INJECTION</td>
<td>Clariscan (gadoterate meglumine) injection for intravenous use</td>
<td>OPTISON (Perfluorcarbon Type A Microspheres Injectable Suspension, USP)</td>
<td>DaTscan I123 Injection (Neurology)</td>
<td>VIZAMYL Flutemetamol F18 Injection (Neurology)</td>
</tr>
<tr>
<td>VISIPAQUE™ (IODIXANOL) INJECTION</td>
<td>OMNISCAN (GADODIAMIDE) INJECTION</td>
<td>SONAZOID™</td>
<td>MYOVIEW™ (Kit for the Preparation of Technetium Tc99m Tetrofosmin for Injection) (Cardiology)</td>
<td>cerianna™ (Oncology)</td>
</tr>
<tr>
<td>ulrichINJECT CT motion™</td>
<td></td>
<td></td>
<td>FASTlab™</td>
<td></td>
</tr>
</tbody>
</table>

### Why We Win in PDx

1. **Continued innovation** across established product portfolio and pipeline to improve clinical effectiveness and efficiency
2. **Scale advantages** through sophisticated vertically integrated supply chain in highly regulated industry
3. **Deep customer relationships** and trust in brand built over many years

### Broad Capabilities with Increasing Focus on Attractive Growth Areas

- (a) For the year 2021; does not include Services or Digital markets
- (b) For the Period 2022-2025

Source: GE HealthCare estimates
Note: Not all products are available worldwide

© 2022, General Electric Company. Proprietary information. All rights reserved.
Contrast Media: Grow Capacity and Innovate

Iodinated (X-Ray) Contrast Media Capacity Expansion

- Demand for iodinated contrast media to double over next decade \(^{(a)}\)
- Expansion of existing API and fill-finish sites; Lean driving productivity
- Recent multi-year iodine supply agreement

Strategy to Drive Growth

**X-Ray**

- Capacity investment and pricing initiatives
- Improve efficiency and reduce waste

**MRI**

- Transform MRI industry with branded-generics
- Develop non-gadolinium alternative MRI agents

**Ultrasound**

- Expand Optison in US and Sonazoid globally
- Increased use of contrast beyond diagnostics

Source: GE HealthCare estimates

(a - Illustrative graph, not to scale)
Molecular Imaging: Growth in Key Care Areas

Leading position in Neurology

- Parkinson’s prevalence is expected to double to ~14M by 2040
- Leading player with DaTscan
- Pipeline aimed at improving workflow and image quality

Building out Oncology platform

- Breast cancer represents 30% of female cancer
- Building out breast oncology platform
- Developing Immuno-oncology toolbox for Pharma with patient selection & therapy monitoring

Innovating in Cardiology

- Coronary artery disease is the leading cause of death globally
- Leading player with established Myoview & Rapiscan products
- Complementing our portfolio with Flurpiridaz, a pipeline PET

Track Record of Delivering Critical Solutions to Enable Life-Saving Disease Detection

(a - Product for Coronary Artery Disease; Completed Phase III clinical trials)
## Pharmaceutical Diagnostics: Pipeline

<table>
<thead>
<tr>
<th>CARE AREA</th>
<th>PROGRAM</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>MARKETING AUTHORIZATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiology</td>
<td>Gd MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-Gd MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>Dopamine transporter PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dopamine transporter SPECT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiology</td>
<td>Myocardial perfusion PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>Estrogen receptor PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Her2 receptor PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno-Diagnostics</td>
<td>CD8 T-Cells PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Robust Pipeline of Products Focused on Key High-Growth Markets**

Note: GE Healthcare retains global rights to all pipeline assets reflected on this page

© 2022, General Electric Company. Proprietary information. All rights reserved.
## Pharmaceutical Diagnostics Historical Financial Summary

### Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>2019A</th>
<th>2020A</th>
<th>2021A</th>
<th>2021 3Q YTD</th>
<th>2022 3Q YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$2.0B</td>
<td>$1.8B</td>
<td>$2.0B</td>
<td>$1.5B</td>
<td>$1.5B</td>
</tr>
</tbody>
</table>

### Segment EBIT Margin

<table>
<thead>
<tr>
<th>Year</th>
<th>2019A</th>
<th>2020A</th>
<th>2021A</th>
<th>2021 3Q YTD</th>
<th>2022 3Q YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margin</td>
<td>34.9%</td>
<td>28.3%</td>
<td>34.3%</td>
<td>36.5%</td>
<td>27.7%</td>
</tr>
</tbody>
</table>

### Key Drivers

- **Growing Procedural Demand Over Next Decade**
- **Rise of Molecular Imaging**
- **Strong Recurring Revenue and Margins**
- **Theranostics Creating Growth Opportunity**
Our Growth Strategies to Drive Long-Term Success

- Expand Capacity to Meet Growing Demand
- Commercial Execution Reflecting Product Value
- Increased R&D Investment in New Imaging Agents
- Capitalize on Attractive Growth Adjacencies
Commercial Strategy & Execution

Catherine Estrampes
U.S. & Canada CEO
Key Takeaways

✔ Trusted partner: strong customer relationships, providing a platform for sustainable growth

✔ Unique customer value proposition: innovative products, technologies, services and solutions

✔ Regional scale: rely on global capabilities to solve complex problems for our customers locally
Trusted Partner With Strong Global Presence

2021 GE HealthCare Revenue

US & Canada: $7.4 billion
EMEA: $4.5 billion
China region: $2.7 billion
Intercontinental: $3.0 billion

- R&D Presence
- Manufacturing Site
- Customer Service

4M+
Installed Base

>10,000
Global Sales Force

1,500
Channel Partners

8,500
Field Engineers

1,800
Clinical Application & R&D Specialists

Focused Operating Model With Four Regional Leaders To Take Advantage of Scale Where It Matters Most
## Unique Value Proposition to Customers

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deep customer relationships</td>
<td>• Rely on GEHC for mission-critical capabilities</td>
</tr>
<tr>
<td>Tailored regional execution</td>
<td>• Multi-channel commercial model</td>
</tr>
<tr>
<td>Technology leader</td>
<td>• Long-standing delivery of industry-defining innovations</td>
</tr>
<tr>
<td>Solutions partner</td>
<td>• Full suite of digital, AI and services platform</td>
</tr>
<tr>
<td>Best-in-class service</td>
<td>• Global scale and dedicated team of highly-trained service engineers</td>
</tr>
</tbody>
</table>

**Well-Positioned To Attract New Customers, Increase Customer Retention And Long-Term Value**
Regional Teams Deliver Solutions at Scale to Customers

Customer Needs

- Addressing labor challenges
- Improving patient throughput
- Navigating capital decisions and cyber risks
- Delivering better patient outcomes
- Cost controls through innovative monitoring

GE HealthCare Customer Team

- Care Pathway Specialists
- Digital and Data Science Specialists
- Clinical Scientists
- Service Engineers
- Product Sales Specialists
- Clinical Application Specialists
- Regional Managers
- Account Managers

Meeting Customer Needs At Scale While Improving Outcomes At Lower Costs
Innovating with HCA to Improve Clinical Experience Care

25-year Partnership Supports Commitment to Care and Improvement of Human Life

35M Annual Patient Encounters

2,500 Sites of Care

DIGITAL & CLINICAL TRANSFORMATION

CLINICAL EXPERIENCE

MODERNIZING WORKFLOW
Financial Strategy

Helmut Zodl
CFO
Our Financial Strategy

1. Accelerating Innovation & Driving Growth

2. Delivering Sustainable, High-Quality Performance

3. Optimizing Business Through Lean

4. Aligning Capital Allocation to Strategy

Driving Growth

- Mid-single Digit Organic Revenue Growth*
- High-teens to 20% Adj. EBIT Margin*
- Strong Free Cash Flow* Generation
- Disciplined Capital Allocation

Significant Shareholder Value Creation Opportunity

*Non-GAAP Financial Measure. Medium-term targets.
Accelerating Innovation & Driving Growth

Revenue Growth

- 3% CAGR for 2019A - 2021A
- Medium-term Target

Growth Drivers

- Customer Demand and Industry Growth
- New Product Introductions and Digital Solutions
- Enhanced Commercial Execution
- Increased R&D Spending

Leadership Positions Across Markets Drive Growth

Note: Illustrative graph, not to scale
* Non-GAAP Financial Measure
(a- on an organic basis)
Investing in R&D to Drive Growth and Margin

Key Actions

- Increase Pace of NPIs at Higher Gross Margins
- Expand Digital / AI Capabilities
- Optimize Product Platforms
- Portfolio / R&D Prioritization Process

$1B+ 2022E R&D

35%+ NPI vitality\(^{a)}\)

Allocating R&D to High ROI Projects

(a - Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months.)
Commercial Execution Delivering Mid-Single Digit Growth

Q3 YTD Organic Revenue Growth* of 6%

Revenues by Segment

<table>
<thead>
<tr>
<th>Segment</th>
<th>2021 Q3 YTD</th>
<th>2022 Q3 YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging</td>
<td>$7.0B</td>
<td>$7.3B</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>$2.3B</td>
<td>$2.5B</td>
</tr>
<tr>
<td>PCS</td>
<td>$2.2B</td>
<td>$2.1B</td>
</tr>
<tr>
<td>PDx</td>
<td>$1.5B</td>
<td>$1.5B</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$13.0B</strong></td>
<td><strong>$13.4B</strong></td>
</tr>
</tbody>
</table>

Organic Revenue Growth*

- Imaging: 8%
- Ultrasound: 2% (0%)
- PCS: 6%
- PDx: 2%

Market Position

- Largest Global Installed Base
- Care Across the Patient Journey
- Global Brand Recognition
- Commercial Infrastructure and Supply Chain Optimization

Delivering More Value for Customers Through Increased Focus on Commercial Excellence

Note: Illustrative graph, not to scale
* Non-GAAP Financial Measure

© 2022, General Electric Company. Proprietary information. All rights reserved.
Delivering Sustainable, High-Quality Performance

Significant Recurring Revenue Driven by Our Industry-Leading Services and PDx Businesses

(a) For the year 2021

Recurring Revenue\(^{a)}\)

\(~50\%\)

Key Drivers

- Lifecycle Services
- Pharmaceutical Diagnostics
- Digital Solutions and Software
- Consumables and Value-Added Offerings
Optimizing Business Through Lean

Adjusted EBIT Margin*

- % of revenue
- Historical
  - 2019A - 2021A: 15% - 18%
  - Target: High-teens to 20%

Implementing Lean to Drive Margins & FCF*

- Sales and Marketing Effectiveness
- Price and Value
- Variable Cost Productivity
- Simplifying Operating Model / G&A

Reinvesting Operational Savings to Driving Top- and Bottom-line Growth

Note: Illustrative graph, not to scale
* Non-GAAP Financial Measure

© 2022, General Electric Company. Proprietary information. All rights reserved.
## Implementing Lean Across our Business

<table>
<thead>
<tr>
<th>Category</th>
<th>Key Focus Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margin Expansion</td>
<td>• Price Improvement vs. Inflation</td>
</tr>
<tr>
<td>Portfolio Optimization</td>
<td>• SKU Rationalization and Configuration Management</td>
</tr>
<tr>
<td>Optimizing CapEx / G&amp;A</td>
<td>• Real Estate Footprint</td>
</tr>
<tr>
<td>Inventory Turns</td>
<td>• Implement Pull Systems to Reduce Lead Times</td>
</tr>
</tbody>
</table>

**Using Lean to Sustainably Improve Our Business Every Day**
Lean Implementation Driving Margin Expansion

Adj. EBIT Margin*

High-teens to 20%

~15%

Lean Margin Drivers

- Commercial Excellence
- Higher Margin Products from Innovation
- Portfolio & Supply Chain Optimization
- Cost and Expense Productivity

Headwinds Exerting Pressure on Near-term EBIT but Long-term Trajectory Remains Intact

Note: Illustrative graph, not to scale

* Non-GAAP Financial Measure

(a) - 2022E GEHC figures consistent with GE Company guide for HealthCare segment of MSD organic revenue growth and operating profit of $2.6B+
Solid Cash Flow Generation and Financial Flexibility

Free Cash Flow Conversion* - a)

85%+

Free Cash Flow* Expected to Grow with Future Earnings
Commitment to Strong Investment Grade Ratings
Maintain Strong Balance Sheet with Flexibility
Strong Liquidity on Day 1 with $1.8B of Cash and $3.5B Credit Facility Availability

Robust Cash Generation Directed Towards Near-Term Debt Repayment and Investment in Organic & Inorganic Growth

* Non-GAAP Financial Measure
(a - FCF conversion* = FCF* / Adjusted Net Income*)
Aligning Capital Allocation to Strategy

**Investing in Organic Revenue Growth**
- ✓ Increasing R&D and Capex
- ✓ Focus on Differentiation and Digital / AI

**M&A**
- ✓ Disciplined Investments
- ✓ Adjacent Opportunities, e.g. BK Medical

**Minority Investments & Strategic Collaborations**
- ✓ Augmented Product Pipeline
- ✓ Early Engagement with Companies for Potential M&A

$2.5B
Cumulative R&D investment from 2019-2021

4
Acquisitions announced since 2020

20+
Investments / collaborations since 2020

Commitment to Maintain Strong Investment Grade Rating with Robust and Consistent Cash Flow
On Track to Finish 2022 with Solid Performance

- **2022E**
  - **Organic Revenue Growth***
  - **Adjusted EBIT***
  - **FCF***

### Outlook

**MSD**
- Continued order book growth
- Greater components access and increased fulfillment

**$2.7B+**
- (equal to $2.6B+ on GE basis)
- Proactive cost and price actions
- Volume growth and productivity

**$1.8 - 2.0B**
- (equal to $2.1 to $2.3B on GE basis)
- Inventory build for ramp in demand
- Focused working capital improvements

---

*Non-GAAP Financial Measure
(a) 2022E GEHC figures consistent with GE Company guide for HealthCare segment of MSD organic revenue growth, operating profit of $2.6B+ and FCF of $2.1-2.3B (after the impact of carve-out adjustments, primarily due to taxes)
Long-Term Value Creation Framework

Driving Growth
MSD Organic Revenue Growth*

Strong FCF* Generation

Adj EBIT Margin Expansion
High-teens to 20%*

Disciplined Capital Allocation
Strong financial position
Investment in Organic growth
Investment in M&A

Shareholder Value Creation

*Non-GAAP Financial Measure. Medium-term targets.
Q&A
Closing Remarks

Peter Arduini
CEO
Significant Value Creation Opportunity

Visibility to Growth

- Solid demand and backlog
- Continued R&D investment
- Commercial execution focus

Expanding Adjusted EBIT Margin*

- Strategic pricing
- Higher-margin products
- Product line simplification

% Revenue Growth

- 2019A - 2021A CAGR
- Medium-term Target

- 3%

% Adj. EBIT Margin*

- Historic 2019A - 2021A
- Medium-term Target

- 15% - 18%
- High-teens to 20%

Growth and Margin Expansion Driving Strong Shareholder Value

Note: Illustrative graph, not to scale
* Non-GAAP Financial Measure
(a- on an organic basis

© 2022, General Electric Company. Proprietary information. All rights reserved.
Driving the Future of Healthcare

Global leader in precision care
- Unparalleled brand, scale, customer relationships and capabilities

Outstanding portfolio of innovative products and solutions
- Breaking new ground across care pathways, devices and digital solutions

Driving growth and margin expansion
- Clear path to MSD organic revenue growth* and high-teens to 20% margins*
Thank You

Upcoming Events:

J.P. Morgan Annual Healthcare Conference
January 10, 2023

4Q'22 Earnings Call
January 30, 2023
DISCLAIMER:

The statements in today’s videos by the following individuals are based on their own opinions and on results that were achieved in their unique settings. Because there is no “typical” hospital and many variables exist, i.e., hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results.

Hollis Potter, M.D.
Tom Schrack
Sonali Basu, M.D.
Alfred Abuhamad
Dr. Ken Herrmann
Mike Schlosser, M.D.
GE HealthCare Command Center customer representatives

Dr. Basu is a paid consultant for GEHC and was compensated for participation in today’s testimonial video. The statements by Dr. Basu are based on her own opinions and on results that were achieved in her unique setting. Because there is no “typical” hospital and many variables exist, i.e., size, case mix, etc. there can be no guarantee that other customers will achieve the same hospital results.
Supplemental Materials
Non-GAAP Financial Measures

The non-GAAP financial measures disclosed in this presentation are supplemental measures of our performance and our liquidity that we believe help investors understand our financial condition, cash flows and operating results and assess our future prospects. We believe that presenting these non-GAAP financial measures, in addition to the corresponding U.S. GAAP financial measures, are important supplemental measures that exclude non-cash or other items that may not be indicative of or are unrelated to our core operating results and the overall health of our company. We believe that these non-GAAP financial measures provide investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes of management.” We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. When read in conjunction with our U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in our underlying businesses and can be used by management as one basis for financial, operational, and planning decisions. Finally, these measures are often used by analysts and other interested parties to evaluate companies in our industry. Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes, thereby affecting their comparability from company to company. In order to compensate for these and the other limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. Readers should review the reconciliations and should not rely on any single financial measure to evaluate our business.

We define these non-GAAP financial measures as:

**Organic revenue**: Total revenues excluding the effects of: (1) net sales from recent acquisitions and divestitures with less than a full year of comparable net sales; and (2) foreign currency exchange rate fluctuations in order to present revenue on a constant currency basis.

**Adjusted EBIT**: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges - net; (2) Non-operating benefit costs; (3) Provision for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net income (loss) attributable to noncontrolling interests; (6) restructuring costs; (7) acquisition, disposition related charges; (8) Spin-Off and separation costs; (9) gain/loss of business dispositions/divestments; (10) amortization of acquisition-related intangible assets; and (11) investment revaluation (gain)/loss.

**Adjusted EBIT margin**: Non-GAAP financial measure of Adjusted EBIT divided by the U.S. GAAP financial measure Total revenues for the same period.

We believe Adjusted EBIT and Adjusted EBIT margin provide management and investors with additional understanding of our business by highlighting the results from ongoing operations and the underlying profitability factors. These metrics exclude interest expense, interest income, and tax expense, as well as unique and/or non-cash items, that can have a material impact on our results. We believe this provides additional insight into how our businesses are performing, on a normalized basis. However, Adjusted EBIT and Adjusted EBIT margin should not be construed as inferring that our future results will be unaffected by the items for which the measure adjusts.

**Adjusted Net Income**: Net income attributable to GE HealthCare excluding (1) Non-operating benefit costs; (2) restructuring costs; (3) acquisition and disposition related charges (benefits); (4) Spin-Off and separation costs; (5) gain/loss of business dispositions/divestments; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain)/loss; (8) tax effect of reconciling items (items 1-7); (9) impact of tax law changes and (10) Income (loss) from discontinued operations, net of taxes. In addition, we may from time to time consider excluding other nonrecurring items to enhance comparability between periods.

We believe Adjusted net income provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how we evaluate our business. Adjusted net income also provides management and investors with additional perspective regarding the impact of certain significant items on our combined earnings. However, Adjusted net income should not be construed as inferring that our future results will be unaffected by the items for which the measure adjusts.

**Free cash flow**: Cash from (used for) operating activities - continuing operations adjusting for the effects of (1) additions to PP&E and internal-use software; (2) dispositions of PP&E; and (3) impact of factoring programs.

We believe that Free cash flow provides management and investors with an important measure of our ability to generate cash on a normalized basis. Free cash flow also provides insight into our flexibility to allocate capital, including reinvesting in the company for future growth, paying down debt, paying dividends, and pursuing other opportunities that may enhance stockholder value. We believe investors may find it useful to compare Free cash flow performance without the effects of the factoring program discontinuation. The cash flow from operating activity (“CFOA”) impact from factoring programs discontinued in 2021 represents the cash that we would have otherwise collected in the period had customer receivables not been previously sold to GE in those discontinued programs.

We typically invest in PP&E over multiple periods to support new product introductions and increases in manufacturing capacity and to perform ongoing maintenance of our manufacturing and distribution operations. We believe that while PP&E expenditures and dispositions will fluctuate period to period, we will need to maintain a material level of net PP&E spend to maintain ongoing operations and growth of the business.

Our historical Free cash flow includes interest expense associated with the internal and external factoring of current receivables and other financial charges. Interest expense associated with external debt that is currently held by GE is not currently included in the combined financial statements and related notes. Additionally, Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact the measures do not deduct the payments required for debt repayments.
### GEHC Organic Revenue Reconciliation

<table>
<thead>
<tr>
<th>($) in Millions</th>
<th>2019</th>
<th>2020</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$16,633</td>
<td>$17,164</td>
<td>3%</td>
<td>$17,164</td>
<td>$17,585</td>
<td>2%</td>
<td>$12,996</td>
<td>$13,403</td>
<td>3%</td>
<td>$4,305</td>
<td>$4,576</td>
<td>6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less: Acquisitions(^a)</td>
<td>--</td>
<td>36</td>
<td>--</td>
<td>19</td>
<td>--</td>
<td>175</td>
<td>--</td>
<td>175</td>
<td>3%</td>
<td>--</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less: Dispositions(^b)</td>
<td>76</td>
<td>21</td>
<td>81</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less: Foreign currency exchange</td>
<td>--</td>
<td>(36)</td>
<td>--</td>
<td>308</td>
<td>--</td>
<td>(484)</td>
<td>--</td>
<td>(484)</td>
<td>--</td>
<td>--</td>
<td>(232)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organic revenue(^*)</td>
<td>$16,557</td>
<td>$17,143</td>
<td>4%</td>
<td>$17,083</td>
<td>$17,258</td>
<td>1%</td>
<td>$12,996</td>
<td>$13,711</td>
<td>6%</td>
<td>$4,305</td>
<td>$4,747</td>
<td>10%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) - Represents revenue attributable to acquisitions from the date we completed the transaction through the end of four quarters following the transaction.

\(^b\) - Represents revenue attributable to dispositions for the four quarters preceding the disposition date.

© 2022, General Electric Company. Proprietary information. All rights reserved.
## Segment Organic Revenue Reconciliation

### Imaging ($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>9M '21</th>
<th>9M '22</th>
<th>% change</th>
<th>3Q '21</th>
<th>3Q '22</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$9,096</td>
<td>$8,959</td>
<td>(2%)</td>
<td>$8,959</td>
<td>$9,433</td>
<td>5%</td>
<td>$6,996</td>
<td>$7,276</td>
<td>4%</td>
<td>$2,351</td>
<td>$2,516</td>
<td>7%</td>
</tr>
<tr>
<td>Less: Acquisitions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Dispositions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Foreign currency exchange</td>
<td></td>
<td>(24)</td>
<td></td>
<td>163</td>
<td>-</td>
<td></td>
<td>-</td>
<td>(255)</td>
<td></td>
<td>-</td>
<td>(125)</td>
<td></td>
</tr>
<tr>
<td>Organic revenue*</td>
<td>$9,096</td>
<td>$8,983</td>
<td>(1%)</td>
<td>$8,959</td>
<td>$9,270</td>
<td>3%</td>
<td>$6,996</td>
<td>$7,530</td>
<td>8%</td>
<td>$2,351</td>
<td>$2,640</td>
<td>12%</td>
</tr>
</tbody>
</table>

### Ultrasound ($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>9M '21</th>
<th>9M '22</th>
<th>% change</th>
<th>3Q '21</th>
<th>3Q '22</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$2,783</td>
<td>$2,703</td>
<td>(3%)</td>
<td>$2,703</td>
<td>$3,172</td>
<td>17%</td>
<td>$2,274</td>
<td>$2,466</td>
<td>8%</td>
<td>$735</td>
<td>$823</td>
<td>12%</td>
</tr>
<tr>
<td>Less: Acquisitions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>174</td>
<td></td>
<td>-</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Less: Dispositions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Foreign currency exchange</td>
<td></td>
<td>(4)</td>
<td></td>
<td>56</td>
<td>-</td>
<td></td>
<td>-</td>
<td>(116)</td>
<td></td>
<td>-</td>
<td>(56)</td>
<td></td>
</tr>
<tr>
<td>Organic revenue*</td>
<td>$2,783</td>
<td>$2,707</td>
<td>(3%)</td>
<td>$2,703</td>
<td>$3,116</td>
<td>15%</td>
<td>$2,274</td>
<td>$2,408</td>
<td>6%</td>
<td>$735</td>
<td>$818</td>
<td>11%</td>
</tr>
</tbody>
</table>

### PCS ($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>9M '21</th>
<th>9M '22</th>
<th>% change</th>
<th>3Q '21</th>
<th>3Q '22</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$2,723</td>
<td>$3,675</td>
<td>35%</td>
<td>$3,675</td>
<td>$2,915</td>
<td>(21%)</td>
<td>$2,180</td>
<td>$2,130</td>
<td>(2%)</td>
<td>$708</td>
<td>$701</td>
<td>(1%)</td>
</tr>
<tr>
<td>Less: Acquisitions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Dispositions</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Foreign currency exchange</td>
<td></td>
<td>1</td>
<td></td>
<td>32</td>
<td>-</td>
<td></td>
<td>-</td>
<td>(48)</td>
<td></td>
<td>-</td>
<td>(22)</td>
<td></td>
</tr>
<tr>
<td>Organic revenue*</td>
<td>$2,723</td>
<td>$3,674</td>
<td>35%</td>
<td>$3,674</td>
<td>$2,883</td>
<td>(22%)</td>
<td>$2,180</td>
<td>$2,178</td>
<td>(0%)</td>
<td>$708</td>
<td>$723</td>
<td>2%</td>
</tr>
</tbody>
</table>

### PDx ($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>% change</th>
<th>2020</th>
<th>2021</th>
<th>% change</th>
<th>9M '21</th>
<th>9M '22</th>
<th>% change</th>
<th>3Q '21</th>
<th>3Q '22</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$1,993</td>
<td>$1,780</td>
<td>(11%)</td>
<td>$1,780</td>
<td>$2,018</td>
<td>13%</td>
<td>$1,518</td>
<td>$1,485</td>
<td>(2%)</td>
<td>$504</td>
<td>$522</td>
<td>4%</td>
</tr>
<tr>
<td>Less: Acquisitions</td>
<td>-</td>
<td>36</td>
<td></td>
<td>-</td>
<td>19</td>
<td></td>
<td>-</td>
<td>2</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Dispositions</td>
<td>76</td>
<td>21</td>
<td></td>
<td>81</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Less: Foreign currency exchange</td>
<td>-</td>
<td>(10)</td>
<td></td>
<td>53</td>
<td>-</td>
<td></td>
<td>-</td>
<td>(64)</td>
<td></td>
<td>-</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>Organic revenue*</td>
<td>$1,917</td>
<td>$1,733</td>
<td>(10%)</td>
<td>$1,699</td>
<td>$1,946</td>
<td>15%</td>
<td>$1,518</td>
<td>$1,547</td>
<td>2%</td>
<td>$504</td>
<td>$552</td>
<td>10%</td>
</tr>
</tbody>
</table>

(a) Represents revenue attributable to acquisitions from the date we completed the transaction through the end of four quarters following the transaction.
(b) Represents revenue attributable to dispositions for the four quarters preceding the disposition date.

* Non-GAAP financial measure.
Adj. EBIT Reconciliation

<table>
<thead>
<tr>
<th>($ in Millions)</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income attributable to GE HealthCare</td>
<td>$1,524</td>
<td>$13,846</td>
<td>$2,247</td>
</tr>
<tr>
<td>Add: Interest and other financial charges – net</td>
<td>88</td>
<td>66</td>
<td>40</td>
</tr>
<tr>
<td>Add: Non-operating benefit costs</td>
<td>9</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Less: Provision for income taxes</td>
<td>(410)</td>
<td>(652)</td>
<td>(600)</td>
</tr>
<tr>
<td>Less: Income (loss) from discontinued operations, net of taxes</td>
<td>(128)</td>
<td>11,839</td>
<td>18</td>
</tr>
<tr>
<td>Add: Net income attributable to noncontrolling interests</td>
<td>29</td>
<td>51</td>
<td>46</td>
</tr>
<tr>
<td>EBIT (Non-GAAP)</td>
<td>$2,188</td>
<td>$2,781</td>
<td>$2,918</td>
</tr>
<tr>
<td>Add: Restructuring costs a)</td>
<td>160</td>
<td>134</td>
<td>155</td>
</tr>
<tr>
<td>Add: Acquisition and disposition related charges (benefits) b)</td>
<td>--</td>
<td>--</td>
<td>14</td>
</tr>
<tr>
<td>Add: Spin-Off and separation costs c)</td>
<td>54</td>
<td>2</td>
<td>--</td>
</tr>
<tr>
<td>Add: (Gain)/loss of business dispositions / divestments d)</td>
<td>(3)</td>
<td>3</td>
<td>(2)</td>
</tr>
<tr>
<td>Add: amortization of acquisition related intangible assets</td>
<td>92</td>
<td>83</td>
<td>90</td>
</tr>
<tr>
<td>Add: investment revaluation (gain)/loss e)</td>
<td>1</td>
<td>(22)</td>
<td>(3)</td>
</tr>
<tr>
<td>Adjusted EBIT (Non-GAAP)</td>
<td>$2,492</td>
<td>$2,981</td>
<td>$3,172</td>
</tr>
<tr>
<td>Net income margin (US GAAP)</td>
<td>9.2%</td>
<td>80.7%</td>
<td>12.8%</td>
</tr>
<tr>
<td>Adjusted EBIT Margin (Non-GAAP)</td>
<td>15.0%</td>
<td>17.4%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

(a - Consists of severance, facility closures, and other charges associated with historical restructuring programs.  
(b - Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.  
(c - Costs incurred in the Spin-Off and separation from GE as well as the planned IPO of GE’s Healthcare business in 2019 including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.  
(d - Consists of gains and losses resulting from the sale of assets and investments.  
(e - Primarily relates to valuation adjustments for equity investments.  

© 2022, General Electric Company. Proprietary information. All rights reserved.
## Adj. Net Income Reconciliation

($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income attributable to GE HealthCare</td>
<td>$1,524</td>
<td>$13,846</td>
<td>$2,247</td>
</tr>
<tr>
<td>Add: Non-operating benefit (income) costs</td>
<td>9</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Add: Restructuring costs &lt;a&gt;</td>
<td>160</td>
<td>134</td>
<td>155</td>
</tr>
<tr>
<td>Add: Acquisition and disposition related charges (benefits) &lt;b&gt;</td>
<td>--</td>
<td>--</td>
<td>14</td>
</tr>
<tr>
<td>Add: Spin-Off and separation costs &lt;c&gt;</td>
<td>54</td>
<td>2</td>
<td>--</td>
</tr>
<tr>
<td>Add: (Gain)/loss of business dispositions/divestments &lt;d&gt;</td>
<td>(3)</td>
<td>3</td>
<td>(2)</td>
</tr>
<tr>
<td>Add: Amortization of acquisition-related intangible assets</td>
<td>92</td>
<td>83</td>
<td>90</td>
</tr>
<tr>
<td>Add: Investment revaluation (gain)/loss &lt;e&gt;</td>
<td>1</td>
<td>(22)</td>
<td>(3)</td>
</tr>
<tr>
<td>Add: Tax effect of reconciling items</td>
<td>(73)</td>
<td>(51)</td>
<td>(62)</td>
</tr>
<tr>
<td>Less: Impact of tax law changes &lt;f&gt;</td>
<td>--</td>
<td>40</td>
<td>77</td>
</tr>
<tr>
<td>Less: Income (loss) from discontinued operations, net of taxes</td>
<td>(128)</td>
<td>11,839</td>
<td>18</td>
</tr>
<tr>
<td>Adjusted Net Income (Non-GAAP)</td>
<td>$1,892</td>
<td>$2,121</td>
<td>$2,347</td>
</tr>
</tbody>
</table>

<a> - Consists of severance, facility closures, and other charges associated with historical restructuring programs

<b> - Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions

<c> - Costs incurred in the Spin-Off and separation from GE as well as the planned IPO of GE’s Healthcare business in 2019 including system implementation, audit and advisory fees, legal entity separation, and other one-time costs

<d> - Consists of gains and losses resulting from the sale of assets and investments

<e> - Primarily relates to valuation adjustments for equity investments

<f> - Consists of benefit from U.K. tax rate change

© 2022, General Electric Company. Proprietary information. All rights reserved.
## Free Cash Flow Reconciliation

($ in Millions)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash from operating activities – continuing operations</td>
<td>$1,838</td>
<td>$2,618</td>
<td>$1,607</td>
</tr>
<tr>
<td>Add: Additions to PP&amp;E and internal-use software</td>
<td>(331)</td>
<td>(259)</td>
<td>(248)</td>
</tr>
<tr>
<td>Add: Dispositions of PP&amp;E</td>
<td>52</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>Add: Impact of factoring programs(^a)</td>
<td>341</td>
<td>88</td>
<td>1,453</td>
</tr>
<tr>
<td><strong>Free cash flow</strong>(^a)</td>
<td><strong>$1,900</strong></td>
<td><strong>$2,463</strong></td>
<td><strong>$2,827</strong></td>
</tr>
</tbody>
</table>

\(^a\) Adjustment to present net cash flows from operating activities from continuing operations had we not factored receivables with WCS. By the end of 2021, factoring of receivables with WCS was discontinued

\(^a\) Non-GAAP financial measure
### Definitions

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>Artificial Intelligence</td>
</tr>
<tr>
<td>API</td>
<td>Active Pharmaceutical Ingredient</td>
</tr>
<tr>
<td>Book to Bill</td>
<td>Total orders divided by total sales within a given financial period (e.g., Quarter or FY)</td>
</tr>
<tr>
<td>CAGR</td>
<td>Compound Annual Growth Rate</td>
</tr>
<tr>
<td>CCTA</td>
<td>Coronary CT Angiography</td>
</tr>
<tr>
<td>CFD</td>
<td>CMOS Flat Detector</td>
</tr>
<tr>
<td>CT</td>
<td>Computed Tomography</td>
</tr>
<tr>
<td>cGMP</td>
<td>Current Good Manufacturing Practices</td>
</tr>
<tr>
<td>DE&amp;I</td>
<td>Diversity, Equity, and Inclusion</td>
</tr>
<tr>
<td>D³</td>
<td>Device, Disease State, Digital</td>
</tr>
<tr>
<td>ECG / EKG</td>
<td>Electrocardiography</td>
</tr>
<tr>
<td>EMR</td>
<td>Electronic Medical Record</td>
</tr>
<tr>
<td>ESG</td>
<td>Environmental, Social, and Governance</td>
</tr>
<tr>
<td>FCF Conversion</td>
<td>FCF* / Adj Net Income*</td>
</tr>
</tbody>
</table>

*Non-GAAP financial measure: See appendix for reconciliations.*
### Definitions (Cont’d)

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGT</td>
<td>Image Guided Therapy</td>
</tr>
<tr>
<td>IDN</td>
<td>Integrated Delivery Network</td>
</tr>
<tr>
<td>MICT</td>
<td>Molecular Imaging and Computed Tomography</td>
</tr>
<tr>
<td>ML</td>
<td>Machine Learning</td>
</tr>
<tr>
<td>MR</td>
<td>Magnetic Resonance</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic Resonance Imaging</td>
</tr>
<tr>
<td>MSD</td>
<td>Mid-Single Digit</td>
</tr>
<tr>
<td>NM</td>
<td>Nuclear Medicine</td>
</tr>
<tr>
<td>NPIs</td>
<td>New Product Introductions</td>
</tr>
<tr>
<td>NVBP</td>
<td>National Volume Based Procurement</td>
</tr>
<tr>
<td>OR</td>
<td>Operating Room</td>
</tr>
<tr>
<td>PCS</td>
<td>Patient Care Solutions</td>
</tr>
<tr>
<td>PCCT</td>
<td>Photon-Counting Computed Tomography</td>
</tr>
<tr>
<td>Definitions (Cont’d)</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDx</td>
<td>Pharmaceutical Diagnostics</td>
</tr>
<tr>
<td>PET</td>
<td>Positron Emission Tomography</td>
</tr>
<tr>
<td>Products</td>
<td>Sales of medical equipment, contrast agents (PDX), software licenses (excludes hosting/SaaS), Options &amp; Upgrades</td>
</tr>
<tr>
<td>Recurring Revenues</td>
<td>Maintenance &amp; repair services for equipment, contrast agents (PDX), Enterprise Digital Solutions (EDS), and other consumables</td>
</tr>
<tr>
<td>RPM</td>
<td>Remote Patient Monitoring</td>
</tr>
<tr>
<td>RSNA</td>
<td>Radiological Society of North America</td>
</tr>
<tr>
<td>Services</td>
<td>Maintenance &amp; repair services for equipment, training, parts, software hosting (Software as a Service (SaaS))</td>
</tr>
<tr>
<td>SPECT</td>
<td>Single-photon Emission Computerized Tomography</td>
</tr>
<tr>
<td>TAM</td>
<td>Total Addressable Market</td>
</tr>
<tr>
<td>VCP</td>
<td>Variable Cost Productivity</td>
</tr>
<tr>
<td>YoY</td>
<td>Year Over Year</td>
</tr>
<tr>
<td>YTD</td>
<td>Year To Date</td>
</tr>
</tbody>
</table>